Skip to main content
. 2021 Oct 15;11(5):363–373.

Figure 3.

Figure 3

Gd-DOTA-labelled β-galactosidase (MW 465 kDa), is able to cross the BBB. Gd-DOTA-β-galactosidase was administered one hour post-OKN-007 treatment, and an increase in MRI signal intensity from the Gd-based contrast agent after administration of OKN-007 (1 hour prior) (A) was detected, compared to a saline control (1 hour prior) also administered the Gd-DOTA-labelled β-galactosidase (B). (C) Percent difference in MRI SI was found to be significantly increased in OKN-007-treated mouse brains administered the Gd-DOTA-β-galactosidase (Gd-DTPA-B-Gal) (n = 6), compared to saline controls (n = 6) (P<0.0001). (D) The percent (%) decrease in T1 relaxation was found to be significantly increased in OKN-007-treated mouse brains administered the Gd-DOTA-β-galactosidase (Gd-DTPA-B-Gal) (n = 6), compared to saline controls (n = 6) (P<0.001).